Senior Management

Alligator Bioscience is guided by a seasoned executive leadership team dedicated to advancing our CD40-targeted immuno-oncology pipeline. Our management, led by CEO Søren Bregenholt and CFO Johan Giléus, brings deep commercial and scientific expertise to drive strategic growth and development.

Søren Bregenholt

CEO

• Independent in relation to the Company and its management: No
• Independent in relation to major shareholders: Yes
• Holdings in Alligator: 105,168 shares, 1,200,000 warrants in program TO 2023/2026 I, and 900,000 warrants in program TO 2024/2027 I.
• Other current positions: Chairman of A Bioscience Incentive AB and Atlas Therapeutics AB, and Board member of Oblique Therapeutics AB (publ).

• Full profile

Johan Giléus

CFO

• Independent in relation to the Company and its management: No
• Independent in relation to major shareholders: Yes
• Holdings in Alligator: 50,000 shares (through company).

• Full profile